Results 1 to 10 of about 756,852 (217)

Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10

Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2020
Background: MiR150-5p has been reported to be involved in generalized myasthenia gravis, in which different cytokines play critical roles. The regulatory network of cytokines in generalized myasthenia gravis has not been fully elucidated. Our study aimed
Xiongjun He, Weidong Wang
exaly   +3 more sources

Refractory generalized myasthenia gravis with myasthenic incomplete ophthalmoplegia successfully treated with eculizumab

American Journal of Ophthalmology Case Reports, 2023
Purpose: This is a case of myasthenic incomplete ophthalmoplegia mimicking a partial cranial nerve 3 palsy both subjectively and objectively improving after treatment with eculizumab.
Sara L. Weidmayer, Gary Gallagher
doaj   +2 more sources

Consistent improvement with eculizumab across muscle groups in myasthenia gravis [PDF]

Annals of Clinical and Translational Neurology, 2020
Objective To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale ...
Renato Mantegazza, Fanny L. O'Brien, Marcus Yountz, James F. Howard Jr, for the REGAIN study group   +4 more
doaj   +5 more sources

Features of depression development in myasthenia gravis. [PDF]

Medičnì Perspektivi, 2020
The relative risk of developing depression in myasthenia gravis is 2.14 times higher than in the general population. The features of depression in myasthenia patients remain poorly understood and need to be clarified.
O. I. Kalbus, S. O. Makarov, N. P. Shastun, O. V. Somilo, Yu. V. Bukreyeva   +4 more
doaj   +2 more sources

Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review

Frontiers in Neurology
BackgroundDespite existing treatments of generalized myasthenia gravis (gMG), there remains a need for more effective therapies with fewer side effects.
Xiaodong Song, Xiaodong Song, Yang He, Hong Jiang, Yao Yu, Yue Sun, Zhaoxu Zhang   +6 more
exaly   +3 more sources

Real-world experience with efgartigimod in generalized myasthenia gravis: a single-center retrospective study in China [PDF]

Frontiers in Immunology
ObjectiveThis study aimed to evaluate the real-world efficacy, safety, and application patterns of efgartigimod in Chinese patients with generalized myasthenia gravis (gMG), with a focus on individualized treatment strategies.MethodsWe conducted a single-
Zhenyu Niu, Jianchun Wang, Jingru Ren, Ran Liu, Jing Guo, Nan Zhang, Yiming Zheng, Hongjun Hao, Feng Gao, Haiqiang Jin   +9 more
doaj   +2 more sources

Clinical characteristics and outcome predictors of a Chinese childhood-onset myasthenia gravis cohort

Frontiers in Pediatrics, 2022
Myasthenia gravis is an organ-specific autoimmune disease. Currently there is no universal guidelines for childhood-onset myasthenia gravis, therefore, treatment strategies are usually based on the guidelines from adult myasthenia gravis patients.
Lifen Yang, Yulin Tang, Fang He, Ciliu Zhang, Miriam Kessi, Jing Peng, Fei Yin   +6 more
doaj   +1 more source

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Neurology and Therapy, 2023
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare ...
Tuan Vu, Andreas Meisel, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Ahmed Enayetallah, Kathleen N. Beasley, Nishi Rampal, James F. Howard   +9 more
doaj   +1 more source

Tatalaksana terkini pada miastenia gravis

Majalah Kedokteran Andalas, 2022
Myasthenia gravis (MG) is a disorder of the neuromuscular junction that causes fluctuating muscle weakness. The etiology of this disease is due to the presence of antibodies that attack acetylcholine receptors on the postsynaptic membrane (autoimmune ...
Lydia Susanti
doaj   +1 more source

Concentric Needle Jitter in 97 Myasthenia Gravis Patients

Frontiers in Neurology, 2020
Objectives: To estimate the jitter parameters (single-fiber electromyography) in myasthenia gravis patients mostly by electrical activation in Frontalis, Orbicularis Oculi, and Extensor Digitorum muscles using a concentric needle electrode.Methods ...
João Aris Kouyoumdjian, Gabriel Pina Paiva, Erik Stålberg   +2 more
doaj   +1 more source